Science Corporation Raised $400 Million to Put Vision Back in Blind Eyes
Science Corporation, the Alameda neurotech startup, raised $400 million in Series D funding to commercialize a vision-restoration system, taking its total funding past $900 million.

A $400 million bet on restoring sight
Science Corporation raised $400 million in Series D funding this week, one of the largest neurotech Series D funding rounds ever, and the money has a specific job. The Alameda, California startup is building a vision-restoration system, and the new capital is meant to commercialize it and fund the next generation of its neural interfaces. The round takes Science's total funding past $900 million, a figure that puts it among the best-funded startups in a field that was, until recently, a research curiosity.
The round led this week's funding news, topping a week that also included a $250 million Series B for Model ML and a $130 million Series D for Galvanize Therapeutics. But Science is the one that matters most, because it is the clearest sign yet that investors now treat brain-computer interfaces as a commercial category rather than a science project. A $400 million Series D is not a bet on a demo. It is a bet on a product that can reach patients.
What Science actually builds
Science works on brain-computer interface technology and neural engineering. Its flagship effort is a vision-restoration system, a device that aims to give sight back to people who have lost it. The company has said relatively little in public about the details of the system, and that restraint is normal for a medical device company. The regulatory path for an implant is long, and the claims a company can make in public are narrow until the clinical data exists.
What the funding tells us is that the investors who have seen the data liked what they saw. A Series D at this size, from investors who have already put hundreds of millions into the company, is a vote of confidence from people with access to the clinical results. The round also funds the next generation of neural interfaces, the hardware that sits between the brain and the outside world, which suggests the company is already thinking past its first product.
The neurotech funding wave
Science is not alone. The neurotech sector has been gathering momentum all year, and the funding numbers show it. Isomorphic Labs raised $5 billion in the same week, the largest financing of the week, and Mirendil raised $1 billion for AI research agents. Those are different fields, but they share a theme: investors are writing very large checks for companies that combine AI with hard science, whether the science is drug discovery or the human brain.
The comparison that matters most for Science is Neuralink, the best-known name in brain-computer interfaces. Neuralink has dominated the public conversation, but Science has been quietly building a different approach, focused on vision rather than general-purpose interfaces. A vision-restoration device has a clearer regulatory path and a clearer patient population than a general brain implant, and that focus may be exactly why investors were willing to write a $400 million check.
What to watch next
The questions that decide whether this round pays off are clinical, not financial. When does the vision-restoration system reach human trials at scale, and what do the results look like? How does the company handle the safety and longevity questions that come with any implant? And can it manufacture the device at a cost that a health system will pay for? None of those questions have public answers yet, and the company will be judged on them over the next two to three years.
For the startup world, the round is a marker. A neurotech company just raised $400 million in a week when the biggest funding story was a $5 billion AI drug discovery round, and nobody treated the neurotech round as a curiosity. The field has arrived. The next test is whether the products arrive too.
The broader funding picture backs that up. In the last seven days alone, startups announced 129 rounds worth $4.2 billion, and the biggest rounds went to companies working on hard problems: brains, metals, space computing, and industrial robots. The easy software rounds are still there, but the money is following the hard stuff. Science Corporation is the clearest example of that shift this week.


